Insilico Medicine uses artificial intelligence to accelerate drug candidate development timelines down to one year. The Hong Kong-based biotech company achieves a candidate nomination timeline of nine to thirteen months by combining generative AI with wet-lab research. This approach demonstrates tangible efficiency gains from AI integration in the pharmaceutical sector, offering a blueprint for accelerated drug discovery pipelines.
Opening Kapyn…